Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR inhibitors may function against FGFR2-amplified GC, and a novel FGFR2-ACSL5 fusion identified by transcriptomic characterization may underlie clinically acquired resistance.
|
28122360 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
A similar incidence of FGFR2 amplification was found in Asian and UK GCs and was associated with lymphatic invasion and poor prognosis.
|
24457912 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
As a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.
|
28002800 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
FGFR2 gene is preferentially amplified and overexpressed in diffuse-type gastric cancer.
|
16773196 |
2006 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
KGFR expression tended to correlate with a good prognosis in gastric cancer.
|
16391783 |
2006 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Approximately 5%-10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification.
|
29177434 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to explore the effects of miR‑494 and FGFR2 in regulation of cancer‑initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2‑positive gastric cancer.
|
29786108 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor-2 (<i>FGFR2</i>) gene is amplified in up to 15% of patients with gastric cancer (GC).
|
31258762 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
|
27230412 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer.
|
27245147 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Applying dual-colour FISH on 137 gastric tumours (89 FFPE surgical resections and 48 diagnostic biopsies), we observed FGFR2 amplification in 7.3% and HER2 amplification in 2.2% of GCs.
|
25086186 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis revealed that high fibroblast growth factor receptor 2 expression was also associated with poor prognosis of gastric cancer, hepatocellular carcinoma, and esophageal cancer, but not correlated with pancreatic cancer.
|
28618942 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Amplifications of certain RTKs (c-Met, FGFR2 and ErbB2) have been associated with human gastric cancer progression.
|
20331976 |
2010 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
|
26516773 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription.
|
27107424 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The FGFR2-inhibitory activity of PRO-007 was confirmed in genetically modified GC cell lines.
|
31396354 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
It will be clinically valuable to investigate the involvement of RTK-mediated signaling in intrinsicor acquired resistance to FGFR2 TKIs in GC.
|
25576915 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The in vivo models established using SGC cell lines are expected to serve as a useful tool for the development of drugs such as FGFR2 inhibitors, TβR inhibitors, and CXCR1 inhibitors, which might be promising as SGC treatments.
|
29876827 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using a three-dimensional organoid tissue model, we functionally validated the metastatic potential of an FGFR2 amplification in gastric cancer.
|
28629429 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
GenomicAlterations
|
disease |
CGI |
|
|
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Deep-sequencing of a primary tumor and metastasis from a single patient, and functional validation in culture, reveals that TGFBR2 and FGFR2 act as drivers of gastric cancer.
|
25222187 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of keratinocyte growth factor and K-sam gene expression in gastric cancer.
|
23545898 |
2013 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The correlations between anti-tumour sensitivity and the molecular segments of HER2, MET and FGFR2 alterations were further tested in a panel of GC cell lines and the patient-derived GC xenograft (PDGCX) model using the targeted inhibitors.
|
24518603 |
2014 |